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Fluoxetine pretreatment blocks DP AT -induced phase shifts, in vitro 
Amanda Wehner 
Introduction 
Circadian rhythms are the manifestations ofthe roughly twenty-four hour cycle of 
behavioral and physiological systems controlled by the internal clock. In mammals, this 
internal clock is located in the suprachiasmatic nucleus (SCN). The SCN is a bilateral 
nucleus in the hypothalamus, consisting of only about 20,000 neurons. It lies just above 
the optic chiasm and on either side of the third ventricle. SCN cells have been shown to 
demonstrate rhythmic firing, glucose uptake, and neurotransmitter release. The overall 
activity of the organism is influenced by the physiological factors controlled by the SCN 
(Herzog and Swartz 2002). 
SCN activity does not function on an exactly twenty-four hour cycle; external and 
physiological factors are constantly resetting it. These constant adjustments are referred 
to as phase shifts. Light input has the strongest impact on SCN rhythmicity. Light input 
to the retina reaches the SCN through the optic nerve. The retino-hypothalamic pathway 
neurons synapse directly on SCN neurons (Moore 1995). Glutamate is the main 
neurotransmitter of this pathway. The presence of light stimulates the release of 
glutamate into the SCN, causing the neurons to produce more activity (Rea 1998). 
However, light input can be modulated by other SCN afferents. 
One of these afferents originates in the midbrain raphe nucleus, widely recognized 
for its involvement in the regulation of brain arousal and consciousness. Serotonin is the 
main neurotransmitter utilized by this pathway. Activity, through the release of 5-HT, can 
modify light-induced-entrainment during the night. During the day, addition of serotonin 
or its agonists to the SCN can induce phase advances on their own (Mistlberger, et al. 
2000, Morin 1999, and Prosser 2003, and Weber, et al. 1998). 
Serotonin acts through many different types of receptors in the SeN and other 
circadian rhythms related areas; such as type-lA, 1B, 1D, 2A, and 7 receptors (Barnes 
and Sharp 1999, Roca, et al. 1993, and Sumner, et al. 1992). DPAT, a serotonin agonist, 
has been shown to cause phase shifts in in vitro SeN experiments (Edgar, et al. 1993). 
The 5-HT7 receptor is known to affect the regulation of circadian rhythms (Lovenberg, et 
al. 1993), and has been found to exist in relatively high densities in the limbic areas, 
including the hypothalamus (Waeber and Moskowitz 1995). Ligands, which bind 
exclusively to the 5-HT7 receptor were shown to advance the mean neuronal activity in 
the rat SeN (Lovenberg, et al. 1993). Sprouse, et al. showed that the phase resetting 
actions of DPAT are sensitive to 5-HT7 receptor antagonists, suggesting this receptor is 
the site of DPAT-binding (2004). 
While serotonin and it agonists have been shown to induce daytime phase 
advances when applied to the SeN in vitro, these effects are not always seen when 
applied in vivo (Antle, et al. 2003, Horikawa and Shibaka 2004, and Bobrzynska, et al. 
1996). Differing levels of endogenous serotonin present in the SeN in vivo versus in vitro 
may cause this discrepancy. The severing of the serotonin afferents during slice 
preparation may lower the level of serotonin present in the SeN, leading to an increase in 
5-HT receptor expression or sensitivity. Thus, acute administration of 5-HT or 5-HT-
agonist could cause a phase advance in vitro while the same treatment would have no 
effect in vivo. 
Fluoxetine is a selective serotonin reuptake inhibitor. Studies have shown that 
treatment with fluoxetine causes decreases in light-induced phase delays if serotonin is 
not already present in the SeN. If serotonin is already present due to sleep deprivation, 
no further decrease in light-induced phase delay is seen, suggesting fluoxetine works 
through the serotonin system (Challet, et al. 2001). Sleight and colleagues showed that 
treatment of rats with fluoxetine causes a significant reduction in the number of 5-HT7 
receptor binding sites in the hypothalamus, suggesting that chronic treatment of 
fluoxetine causes the receptor to be down-regulated in the hypothalamus of the rat 
(Sleight, et ai. 1995). Pretreatment with fluoxetine should raise the effective level of 
serotonin in the slice by blocking the reuptake of released serotonin (Mullins, et ai. 1999). 
Duncan, et ai. also showed that chronic antidepressant treatment reduced agonist-induced 
phase advances, as with DPAT (1999). In light of these data, we hypothesized that, by 
increasing the effective serotonin levels, in the SCN, fluoxetine treatment of the SCN 
brain slices would block serotonergic phase shifts. If fluoxetine treatment blocks the in 
vitro DPAT-induced phase advances, it provides support for the theory that the difference 
between endogenous levels of serotonin in vivo and in vitro is a possible cause for the 
different responses to acute serotonin administrations. 
Methods 
Brain slice preparation 
Coronal brain slices (500 !-lm) containing the SCN were prepared during the daytime 
from adult, male C57BLlJ6 mice, housed in a 12-hour light/dark cycle, where ZT 0 is 
lights on and ZT 12 is lights off. ZT stands for zeitgeberger time. Slices were prepared 
between ZT 0-2. Slices were maintained at the interface of a Hatton-style brain slice 
chamber (Hatton, et aI., 1980) in which they were perfused continuously with warm 
(37°C), oxygenated (95% 0 2/5% CO2), glucose-bicarbonate-supplemented Earle's 
Balanced Salt Solution (EBSS; Sigma, St. Louis, MO), pH 7.4-7.5. 
Experimental Treatments 
The drugs used in phase-shifting experiments were applied during day 1 in vitro by 
stopping the perfusion and replacing the medium in the slice chamber with medium 
containing the test compound. Following the treatment period, normal medium was 
replaced in the slice chamber and perfusion was restored. Fluoxetine was applied for 1 
hour from ZTS-6 and (+) 8-hydroxy-2-(di-n-propylamino) tetralin [DPAT] was applied 
for 10 minutes starting at ZT 6. 
Single unit recordings and data analysis 
Single-unit recordings commenced early on day 2 in vitro. For the treatment slices, 
recording began approximately 18 hours following treatment. The procedure followed 
was described previously (Prosser, et aI., 1993). The spontaneous activity of single SCN 
neurons was recorded using glass capillary micro electrodes filled with 3M NaCl. Each 
neuron was recorded for approximately 5 minutes, and the data was stored for later 
analysis using a DataWave system (DataWave Technologies, Longmont, CO). In general, 
four to seven cells were recorded each hour. These firing rates were then used to calculate 
2 hour running averages, lagged by 1 hour, to obtain a measure of population neuronal 
activity. The time of peak neuronal activity was assessed by visually estimating, to the 
nearest quarter hour, the time of symmetrically highest activity. Phase shifts were 
calculated as the difference in time of peak of untreated slices vs. drug-treated slices. 
Results 
Control experiments 
The SCN neuronal activity recordings obtained from untreated mouse slices on 
the 2nd day in vitro demonstrated a peak in activity near mid-subjective day. The mean of 
peak activity was ZT 6.0 +/- 0.71 (n=3). An example of an untreated slice's neuronal 
rhythm is shown in Figure 1. 
DPAT treatment causes phase advances in vitro 
One set of experiments consisted of brain slices which were treated for 10 
minutes at ZT 6 on day 1 in vitro with 10)lM DPAT, shown in figure 2. These slices 
exhibited a mean time of peak activity at ZT 2.85 +/- 0.17 (n=5), indicating a phase 
advance of 3.15 hours, which is statistically significant. 
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Figure 1. Control. Shown are the 2 hour means +/- SEM Figure 2. IOIlM DP AT induces phase advance when 
of SCN neuronal activity in a control experiment that applied at ZT 6. Shown are the 2 hour means +/- S. E. M. 
peaked at ZT 6.0 +/- 0.71 (n=3). Horizontal bars: time of of SCN neuronal activity obtained after treatment with 10 
lights off in the colony; dotted line: mean time of peak in IlM DPAT. The mean time of peak after DPAT treatment 
control experiments. was ZT 2.85 +/- 0.17 (n=5), demonstrating a phase 
advance of 3.15 hours. Horizontal bars: time of lights off 
in the colony; vertical bar: time of drug treatment; dotted 
line: mean time of peak in control experiments. 
Fluoxetine causes no phase shifts of mouse seN in vitro 
Two series of experiments tested the effects of Fluoxetine treatment on the 
neuronal activity pattern. In the first series of experiments, the slices were treated with 20 
)lM Fluoxetine from ZT5-6 on day 1 in vitro. They exhibited a mean time of peak activity 
at ZT 5.0 +/- 0.58 (n=3), which is not a significant phase shift. The results of one of these 
experiments are seen in Figure 3. In the second series, the slices were treated with 200 
/-lM Fluoxetine from ZT5-6 on day 1 in vitro. These slices showed a mean time of peak 
activity at ZT 5.08 +/- 0.1 (n=3), which also does not show a significant phase shift. The 
results of one of these experiments are shown in Figure 4. 
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Figure 3. Fluoxetine no significant phase shift. Shown are 
the 2 hour means +/- SEM of SCN neuronal activity 
Figure 4. Fluoxetine no significant phase shift. obtained after treatment with 20llM Fluoxetine. The mean 
time of peak activity was ZT 5.0 +/- 0.58 (n=3), Shown are the 2 hour mean +/-SEM ofSCN 
demonstrating no significant phase shift. See figure 2 for neuronal activity obtained following treatment 
legend. with 200llM Fluoxetine. The mean time of peak 
activity was ZT 5.08 +/- 0.1 (n=3), demonstrating 
no significant phase advance. See figure 2 for 
legend. 
Pretreatment with Fluoxetine blocks DPAT-induced phase shifts 
In the next set of experiments, slices were pretreated from ZT 5-6 with 20 /-lM 
Fluoxetine before the 10 minute DP AT treatment. In these experiments, DP AT continued 
to induce phase shifts, such as is shown in Figure 5. In the final set of experiments, slices 
were pretreated with 200 /-lM Fluoxetine from ZT 5-6, followed by the 10 minute DP AT 
treatment. These slices demonstrated a mean time of peak activity at ZT 6.08 +/- 0.1 
(n=3), showing a complete block of the DPAT-induced phase advance. These 
experiments are represented in Figure 6. 
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Figure 5. 20 11M Fluoxetine pretreatment not sufficient Zeilgeber time (hr) 
to block DPAT-induced phase advance. Shown are the Figure 6. Pretreatment with 200 11M Fluoxetine blocks 
2 hour means +/- SEM of SCN neuronal activity DPAT-induced phase shift. Shown are the 2 hour 
following treatment with 20llM Fuoxetine and IOIlM means +/- SEM ofSCN neuronal activity follwing 
DPAT. The mean time of peak activity was ZT 4.0 +/- treatment with 200ilM fluoxetine and 10 11M DPAT. 
O.IS (n=3), showing a phase advance of 2 hours, which The mean time of peak activity was ZT 6.0S +/- 0.1 
is not significantly different from the peak activity (n=3), showing a phase delay ofO.OS hours. Therefore, 
following DPAT treatment alone. See figure 2 for this concentration offluoxetine completely blocked the 
legend. phase advance induced by DP AT. See figure 2 for 
legend. 
Figure 7 summarizes the phase advances seen by all the treatment groups. As seen in the 
histogram, DP AT alone causes the most robust phase advance and pretreatment with 200 
~M Fluoxetine completely eliminates this phase advance. 
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Figure 7. DPAT-induced phase shifts 
are dose-dependently blocked by 
fluoxetine. Shown are the mean phase 
shifts induced by the different 
treatments. The * shows phase shifts 
which are significant (p<0.05) vs. the 
control. 
Discussion 
The results of these experiments clearly demonstrate that the DPAT-induced 
phase advance can be blocked by pre-treatment with Fluoxetine in a dose-dependent 
manner. These results may provide an explanation for the discrepancy between the 
effects of in vivo and in vitro treatments with DPAT. Previous studies with in vivo 
injection of DPAT into the SeN have shown no phase advances (Antle, et al. 2003), 
while work with DP AT treatments in vitro, as seen in this experiment, have shown a 
robust phase advance (Prosser 2000). 
It is possible that fluoxetine pretreatment blocks in vitro phase advances by DP AT 
because it produces conditions that more closely mimic the in vivo environment. 
Fluoxetine blocking 5HT reuptake may raise the effective concentration of serotonin 
present in the slice. This rise in effective serotonin levels may desensitize the clock to 
serotonin, causing the DP AT treatment not to produce a phase shift. One study provides 
additional support for this hypothesis. They showed that in vivo 5-HT administration to 
the seN induces robust phase advances when animals have been pretreated with a 
serotoin antagonist which reduces 5-HT levels in the SeN (Ehlen, et al. 2001). The fact 
that lowering the in vivo 5-HT levels allows serotonergic phase shifts to be expressed 
lends credence to the hypothesis that the different effects seen in vivo and in vitro are due 
to different levels of endogenous serotonin stimulation in the two conditions. 
While these experiments show a block of the DPAT-induced phase advance, they 
do not show how or at what level the fluoxetine is working to block the phase advance. 
The fluoxetine induced increase in effective serotonin concentration may be acting 
directly on the receptor, causing a decrease in sensitivity. However, it may also be acting 
further down the signaling pathway. Further studies to show the effects of blocking 
downstream pathways on the blockage of the phase advance could help to elucidate the 
mechanism offluoxetine's effect on the DPAT-induced phase advance. Understanding 
how fluoxetine is acting to affect circadian rhythms may help to mitigate or explain side 
effects shown in those using fluoxetine as an anti-depressant. If the mechanism of 
fluoxetine action can be illuminated, these side effects may be more easily treatable. 
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